Considerations for Patient-reported Outcomes in the Management of Metastatic Renal Cell Carcinoma.

IF 5.6 2区医学 Q1 UROLOGY & NEPHROLOGY

European urology focus Pub Date : 2025-07-04 DOI:10.1016/j.euf.2025.06.003

Andrew Schlager, Jasnoor Malhotra, Cristiane Decat Bergerot

引用次数: 0

Abstract

Selection of the most appropriate patient-reported outcome measures is essential for accurate assessment of wellbeing in metastatic renal cell carcinoma (RCC). Existing tools provide useful information, but a more nuanced and comprehensive approach is necessary to capture the full scope of patient experiences. FKSI-23 is a new tool with distinct scoring options for localized and advanced RCC. Pending validation, its adoption could better align clinical evaluation with the realities of patients' lived experiences.

查看原文本刊更多论文

转移性肾细胞癌治疗中患者报告结果的考虑。

选择最合适的患者报告的结果测量对于准确评估转移性肾细胞癌（RCC）的健康至关重要。现有的工具提供了有用的信息，但需要更细致和全面的方法来捕捉患者的全部经验。FKSI-23是一种新的工具，具有不同的评分选项，用于本地化和高级RCC。在验证之前，它的采用可以更好地将临床评估与患者生活经历的现实结合起来。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European urology focus Medicine-Urology

CiteScore

10.40

自引率

3.70%

发文量

274

审稿时长

23 days

期刊介绍： European Urology Focus is a new sister journal to European Urology and an official publication of the European Association of Urology (EAU). EU Focus will publish original articles, opinion piece editorials and topical reviews on a wide range of urological issues such as oncology, functional urology, reconstructive urology, laparoscopy, robotic surgery, endourology, female urology, andrology, paediatric urology and sexual medicine. The editorial team welcome basic and translational research articles in the field of urological diseases. Authors may be solicited by the Editor directly. All submitted manuscripts will be peer-reviewed by a panel of experts before being considered for publication.